Survival Rate in Curative Resection of Pancreatic Cancer Patients at Maharat Nakhon Ratchasima Hospital
Abstract
Objective: Pancreatic cancer is difficult to diagnose and treat. Survival rate of pancreatic cancer is also dismal and many clinicopathologic factors are related to survival. The aims of the present study were to determine the 5-year survival rate and prognostic factors associated with survival in pancreatic cancer patients undergoing curative resection.
Patients and Methods: Pancreatic cancer patient data were collected from medical records between January 1, 2009 and June 30, 2012. The primary outcome was overall survival by Kaplan-Meier method. Univariate and multivariate Cox proportional hazard regression analysis was used to determine independent prognostic factors.
Results: Median survival time was 14.3 months and 5-year survival rate was 10.3%. From Cox univariate regression analysis, independent and significant factors predicting the survival of these patients included tumor size, intraoperative blood loss, pathological margin, and lymph node involvement (p < 0.05). From Cox multivariate regression analysis only pathological margin, and intraoperative blood loss were significantly associated with survival (p < 0.05).
Conclusion: In this study, pathological margin and intraoperative blood loss significantly affected overall survival.
References
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
Hidalgo M, Cascinu S, Kleeff J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology 2015;15:8-18.
Nieß H, Kleespies A, Andrassy J, et al. Pankreaskarzinom im hohen Alter: Leitlinien und individualisierte Therapie [Pancreatic cancer in the elderly: guidelines and individualized therapy]. Chirurg 2013;84:291-5.
Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993;165:68-72.
Organization WHO. World cancer Report 2014. Accessed 06 october 2018.
Kongkam P, Benjasupattananun P, Taytawat P, et al. Pancreatic cancer in an Asian population. Endosc Ultrasound 2015;4:56-62.
American Cancer Society. Cancer Facts & Figures 2021. Atlanta: American Cancer Society; 2021.
United States National Cancer Institute. Pancreatic Cancer: Statistics 2018, May.
Allema JH, Reinders ME, van Gulik TM, et al. Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer 1995;75:2069-76.
Ardengh JC, de Paulo G A, Ferrari AP. Pancreatic carcinomas smaller than 3.0 cm: endosonography (EUS) in diagnosis, staging and prediction of resectability. HPB 2003;5:226–30.
Riediger H, Keck T, Wellner U, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009;13:1337-44.
Liu ZQ, Xiao ZW, Luo GP, et al. Effect of the number of positive lymph nodes and lymph node ratio on prognosis of patients after resection of pancreatic adenocarcinoma. Hepatobiliary Pancreat Dis Int 2014;13:634-41.
Yamamoto T, Uchida Y, Terajima H. Clinical impact of margin status on survival and recurrence pattern after curative-intent surgery for pancreatic cancer. Asian J Surg 2019;42:93–9.
Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997;225:621-33.
Bassi C, Marchegiani G, Dervenis C, et al. International Study Group on Pancreatic Surgery (ISGPS). The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery 2017;161:584-91.
Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet 2011;378:607-20.
Lambert A, Schwarz L, Ducreux M, et al. Neoadjuvant treatment strategies in resectable pancreatic cancer. Cancers 2021;13:4724.doi.org/10.3390/cancers13184724.
Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-79.
Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996;223:273-9.
Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995;221:721-31.
Chandrasegaram MD, Goldstein D, Simes J, et al. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. Br J Surg 2015;102:1459-72.
Chang DK, Johns AL, Merrett ND, et al. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 2009;27:2855-62.
Gebauer F, Tachezy M, Vashist YK, et al. Resection margin clearance in pancreatic cancer after implementation of the Leeds Pathology Protocol (LEEPP): clinically relevant or just academic? World J Surg 2015;39:493-9.
Nagai S, Fujii T, Kodera Y, et al. Impact of operative blood loss on survival in invasive ductal adenocarcinoma of the pancreas. Pancreas 2011;40:3–9.
Tamagawa H, Aoyama T, Yamamoto N, et al. The impact of intraoperative blood loss on the survival of patients with stage II/III pancreatic cancer. In Vivo 2020;34:1469-74.
Zhao B, Huang X, Lu H, et al. Intraoperative blood loss does not independently affect the survival outcome of gastric cancer patients who underwent curative resection. Clin Transl Oncol 2019;21:1197-206.
Jagoditsch M, Pozgainer P, Klingler A, et al. Impact of blood transfusions on recurrence and survival after rectal cancer surgery. Dis Colon Rectum 2006;49:1116-30.
Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006;2006:CD005033.
Angele MK, Faist E. Clinical review: immunodepression in the surgical patient and increased susceptibility to infection. Crit Care 2002;6:298-305.
Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 2008;15:165-74.
Berger AC, Watson JC, Ross EA, et al. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2004;70:235-40.
Riediger H, Keck T, Wellner U, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009;13:1337-44.
Petrou A, Soonawalla Z, Silva MA, et al. Prognostic indicators following curative pancreatoduodenectomy for pancreatic carcinoma: A retrospective multivariate analysis of a single centre experience. J BUON 2016;21:874-82.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 The Royal College of Surgeons of Thailand
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles must be contributed solely to The Thai Journal of Surgery and when published become the property of the Royal College of Surgeons of Thailand. The Royal College of Surgeons of Thailand reserves copyright on all published materials and such materials may not be reproduced in any form without the written permission.
